INNT
TOTAL INVALIDATION PROCESSED BY THE IB
12/25/2025
Back to search
Official data from USPTO
PEMPFIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
12/26/2025
Trademark type
Word
Nice classes
5
Filing date
06/02/2016
Registration date
04/10/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/25/2024
Last transaction
12/26/2025
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
ES
Examiner
TOOLEY,DAVID E
Law office
M30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
N. S. (pessoa física)
Immungenetics AG
Representatives
Holiday W. Banta Ice Miller LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and biochemical pharmaceutical preparations for the treatment of or prevention against inflammatory diseasescancerinfectious diseasesfungal diseasesdiseases caused by parasiteseye diseasesdiseases of the central and peripheral nervous systemscardiovascular diseasesdiseases affecting the immune systemgenetic diseasessingle gene disordersmouthteethskinhair and ear diseasesbone and blood diseases as well as reproductive system diseases; pharmaceutical and biochemical pharmaceutical preparations for contraception; biochemical and chemical pharamceuticals preparations for use with inflammatory diseasesin particular for use with chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against inflammatory diseasesin particular for prevention against chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory skin diseases; biochemical and chemical products for prevention against psoriasislupus erythematodes; biochemical and chemical pharmaceuticals preparations for prevention against blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus diseases; biochemical and chemical pharmaceuticals preparations for prevention against pemphigus vulgarispemphigus foliaceusparaneoplastic pemphigus; biochemical and chemical pharmaceuticals preparations for prevention against subepidermal bullous autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for prevention against bullous pemphigoidpemphigoid gestationislinear IgA dermatosismucosal pemphigoidlichen planus pemphigoideanti-laminin gamal/p200 pemphigoidepidermolysis bullosa acquisitadermatitis herpetiformisin particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for prevention against chronic and autoimmune inflammatory diseases of the central nervous systemsin particular for prevention against multiple sclerosis; biochemical and chemical pharmaceuticals preparations for the treatment of inflammatory diseasesin particular for the treatment of chronic and autoimmune inflammatory diseases; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory skin diseasesin particular for the treatment of psoriasislupus erythematodes; biochemical and chemical pharmaceuticals preparations for the treatment of blister-forming autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus diseases; biochemical and chemical pharmaceuticals preparations for the treatment of pemphigus vulgarispemphigus foliaceusparaneoplastic pemphigus; biochemical and chemical pharmaceutical preparations for the treatment of subepidermal bullae autoimmune dermatoses; biochemical and chemical pharmaceuticals preparations for the treatment of bullous pemphigoidpemphigoid gestationislinear IgA dermatosismucosal pemphigoidlichen planus pemphigoidanti-laminin gamal/p200 pemphigoidepidermolysis bullosa acquisitadermatitis herpetiformisin particular against bullous pemphigoid; biochemical and chemical pharmaceuticals preparations for the treatment of chronic and autoimmune inflammatory diseases of the central nervous systemin particular for the treatment of multiple sclerosis; topical and transdermal pharmaceuticalsin particular creamsdispersionslotionsointmentsfluidssolutionsspraysplasterslacquer and filmforming solutionsfor the prevention and treatment of skin diseases of the uppermost skin layer or the upper skin layers; surface treatment pharmaceuticals preparations for use as treatments of immune system diseasesinflammatory diseasesskinhair and ear diseases; oral administration pharmaceuticals preparationsin particular pillstabletslozengescapsulesliquidssolutionsdropsfor the prevention and treatment of central nervous system diseases
Publications
History of USPTO decisions and trademark events.
34 publications found
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
12/04/2025
INPC
INVALIDATION PROCESSED
12/04/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
06/25/2025
C71T
CANCELLED SECTION 71
10/25/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
04/10/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/30/2021
CHLD
CHANGE OF OWNER RECEIVED FROM IB
04/30/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/26/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/24/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/30/2018
FIMP
FINAL DISPOSITION PROCESSED
07/30/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/10/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
04/10/2018
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/21/2018
PUBO
PUBLISHED FOR OPPOSITION
01/23/2018
GPNX
NOTIFICATION PROCESSED BY IB
01/19/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/03/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/03/2018
NPUB
NOTICE OF PUBLICATION
01/03/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/19/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/27/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/27/2017
ALIE
ASSIGNED TO LIE
11/19/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/08/2017
RFNT
REFUSAL PROCESSED BY IB
08/18/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/01/2017
RFRR
REFUSAL PROCESSED BY MPU
08/01/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/01/2017
CNRT
NON-FINAL ACTION WRITTEN
07/31/2017
MAFR
APPLICATION FILING RECEIPT MAILED
07/25/2017
DOCK
ASSIGNED TO EXAMINER
07/19/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/19/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/13/2017
Continuous trademark protection
Get notified about every new filing that threatens PEMPFIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.